







A systematic review of economic evaluations of the use of memantine alone or combined with donepezil for moderate to severe Alzheimer's disease

Ione Ayala Gualandi de Oliveira¹ 
Rosângela Caetano¹ 
Ricardo Ewback Steffen¹ 
Aline Navega Biz¹ 

Abstract

Objective: To synthesize the available evidence and state of the art of economic evaluations which evaluate the use of memantine, whether alone or combined with donepezil, for moderate to severe Alzheimer's disease (AD), focusing on the analytical decision models built. **Method:** The electronic databases MEDLINE, EMBASE, NHS EED, CEA Registry and LILACS were searched for references. After duplicates were removed, two independent reviewers evaluated the titles and abstracts and subsequently the full texts. The Drummond M. tool was used to evaluate the quality of the studies. **Results:** After the application of the eligibility criteria, twelve complete economic evaluations were included. One evaluation was a clinical trial, two involved simulations and nine used Markov models. The main outcome measure adopted was dominated by cost per quality adjusted life year (QALY). The use of memantine was considered cost-effective and dominant in eight studies; while in a single study, its use was dominated when compared to donepezil for moderate AD. Sensitivity analyzes were systematically performed, with robust results. The quality assessment indicated that the methodological quality of the studies was good. **Conclusion:** Although there is some controversy regarding the benefits derived from the use of memantine, whether combined or not with donepezil, the evidence collected suggests that it is cost-effective in the countries where the studies were performed. However, local economic studies need to be performed, given the significant variability derived from the different parameters adopted in the evaluations.

Keywords: Alzheimer Disease. Memantine. Cost and Cost Analysis. Review.

¹ Universidade do Estado do Rio de Janeiro (UERJ), Instituto de Medicina Social. Rio de Janeiro, RJ, Brasil.

The authors declare that there are no conflicts of interest in relation to this study.

No funding was provided for this study.

Correspondence
Ione Ayala Gualandi de Oliveira
ionegualandi@yahoo.com.br

Received: January 06, 2019
Approved: September 18, 2019

INTRODUCTION

Alzheimer's Disease (AD) represents a serious public health problem, as it is the main cause of cognitive decline and dementia in adults, especially older adults. Its diagnosis is primarily clinical, based on the application of standardized criteria, and it progresses with damage to memory and other cognitive and behavioral functions¹.

AD affects around 25 million people around the world² and projections suggest that this total may reach 100 million by 2050³. In addition, a meta-analysis published in 2013 reports that the prevalence of dementias, standardized by age, varies between 5% and 7% in those aged 60 or older, and is higher in less developed countries, most of all in Latin America⁴.

It is estimated that, in 2030, the elderly population in Brazil will reach approximately 41.6 million and that by 2060, one in every three Brazilians will be older than 60⁵. Brazilian studies have indicated a prevalence of dementia in the population aged over 65 of 7.1%, with AD responsible for more than 44% of cases⁶.

There is currently no cure for AD and the impact of the illness on patients and caregivers leads to political pressure to ensure that all the possible treatments are widely available. In addition, there are limited options in terms of interventions during the course of the disease, which include two main groups of drugs.

Acetylcholinesterase inhibitors represent the first line of treatment of mild to moderate AD. Their use is based on the reduction of the cholinergic deficit, through the inhibition of the enzymes that degrade acetylcholine, increasing its synaptic availability and improving cognitive symptoms¹. Memantine is a non-competitive NMDA (N-Methyl-D-Aspartate) glutamate receptor antagonist. It is the only drug in its class used in humans and is approved by the Food and Drug Administration, the European Medicines Agency and the National Health Surveillance Agency for the treatment of moderate to severe AD^{7,8}.

Studies on the efficacy of memantine in severe AD have produced controversial results. The drug's ability to delay symptom worsening and improve

the functional capacity of patients with moderate to severe AD was originally demonstrated in two phase III randomized controlled clinical trials (RCCT)^{9,10}, both with a very short follow-up of 24 weeks.

Other trials, however, have failed to show such favorable results in measures of cognitive function and activities of daily living¹¹. Meta-analyses examining the efficacy of memantine used alone or in combination with anticholinesterase inhibitors have found that improvements in cognitive functions and activities of daily living in patients with moderate to severe AD when present were systematically small in scale¹²⁻¹⁴. The evidence is also conflicting in terms of behavioral and neuropsychiatric symptoms¹⁵. In contrast, although usually mild to moderate, patients on memantine may experience headaches, dizziness, fatigue, mental confusion, and hallucinations¹⁰. Some other aspects that undermine the available evidence on the efficacy of memantine are worth mentioning: some RCCTs had small sample sizes, significant follow-up losses, received direct funding, or had authors who declared having received different types of funding from the pharmaceutical industry, and, therefore, potential conflicts of interest could not be excluded¹⁶.

Due to the transient efficacy of AD treatment drugs, the progression to functional dependence continues even with their use¹⁷. In addition, they are often difficult to use due to their adverse events, such as hypertension, drowsiness and central nervous system-related disorders, and interactions with other drugs.

Considering the harm-benefit ratio as unfavorable, with low efficacy results and potentially significant adverse events in frequency and severity, the French Ministry of Health decided that as of August 2018 anticholinesterases and memantine would no longer be reimbursed by the national health insurance system. At the end of 2016, the Pharmacoeconomic Transparency Committee, which makes recommendations on public drug reimbursement in France, concluded that these drugs did not bring sufficient clinical benefits and called for their exclusion from the list of publicly provided drugs in France, which only became official following the *Haute Autorité de Santé* report

in May 2018^{18,19}. The drug, however, is still present in clinical treatment protocols and is reimbursed in other countries, such as through Medicare in the US, the UK and Australia²⁰.

In Brazil, anticholinesterases have been available in the Unified Health System (or SUS) since 2002, restricted to patients with mild to moderate forms of the disease²¹. Memantine, however, was only incorporated within the SUS for the treatment of moderate and severe AD in 2017⁷. Even before that, however, it was bought by the Ministry of Health (MoH), with a total purchase of approximately 33,000 10mg tablets between 2010 and 2014, to meet judicial orders²².

The burden of disease and the costs associated with AD, population aging, and the lack of disease-modifying treatment options raise concerns about the efficient use of resources. While current legislation in Brazil requires comparative cost-effectiveness evidence for the incorporation of a new technology into the SUS²³, economic evaluation studies have not been carried out by the Ministry of Health, with their introduction into the system being justified by clinical data and the drug's incorporation into the payment systems of other countries⁷.

Given the uncertainties in literature, the present study aimed to synthesize the evidence available in economic studies regarding the use of memantine, whether alone or combined with donepezil, to treat moderate to severe AD, focusing on the analytical decision models used in these evaluations.

METHOD

This systematic review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)²⁴ guidelines and registered with the PROSPERO International Prospective Register of Systematic Reviews under N°. CRD42017076469, in October 2017.

Study identification and search strategy

The MEDLINE, EMBASE, and LILACS bibliographic databases, as well as the Cochrane

Collaboration and specific bases for economic studies – the NHS Economic Evaluation Database (NHS EED), the Database of Abstracts of Reviews of Effects (DARE) and the Cost-Effectiveness Analysis (CEA) Registry - were used to search for studies published up to March 2017.

Search strategies were developed for each database based on specific descriptors, combined with the Boolean operators for AD and the drugs of interest (donepezil and memantine), using specific filters for economic studies. Search strategies specific to each database can be obtained by correspondence with the authors.

There was no restriction on publication period or language in the search. Narrative and systematic reviews of economic studies on the subject were examined for cross-references that might not otherwise have been identified.

References identified in electronic databases were managed using the ENDNOTE[®] software (version X4) for the elimination of duplicates.

Study selection

The articles were selected in two stages (titles and abstracts and, later, the full text), by two reviewers (IAGO and ANB), with disagreements resolved by consensus or, when necessary, through consultation with a third reviewer (RC).

To be included, studies were required to meet the following eligibility criteria: either primary studies (economic assessments conducted through observational studies and randomized controlled trials) or modeling studies related to the use of memantine, whether alone or in combination with donepezil, in adult patients diagnosed with moderate to severe AD, with disease severity determined by a specified assessment scale. Only complete economic assessments (cost-effectiveness analysis, cost-utility analysis or cost-benefit analysis) with the clear identification of comparators (placebo, no specific treatment, galantamine, rivastigmine or donepezil anticholinesterases or other types of non-pharmacological treatment) and measures of

outcome, such as cost per year of life gained, cost per quality adjusted life year (QALY) and cost per time spent in a non-dependent state, were considered. All studies written in English, Portuguese and Spanish were included.

Letters, editorials, narrative reviews, partial economic assessments, and studies that did not contain explicit information on the methods and criteria defined above were excluded.

Methodological Quality Assessment

The quality assessment of the included economic studies was also performed by two independent reviewers (IAGO and RES), with disagreements resolved as described above.

The tool developed by Drummond M.²⁵ was used. It presents 35 evaluation items, distributed in three sections: aspects of study design; sources and quality of the collected data; data analysis and interpretation of results. Six additional items were introduced: data related to the presence of subgroup analysis, study limitations, potential for generalization of results, declarations of conflict of interest and study funding.

Each item was judged as *yes*, *no*, *not clear*, or *not-applicable*.

Data extraction

The relevant data were independently extracted by two reviewers and recorded in a standardized electronic form built on EPIDATA software, with disagreements resolved by a third reviewer.

Data were extracted related to (i) study identification; (ii) general characteristics of economic assessments (type and design of study; country; characteristics of population studied; type of intervention and comparator; measure of effectiveness adopted and data source; types and details of included costs; currency and year of reference; Alzheimer's disease progression model; outcomes; presence of cost-effectiveness threshold)

(iii) general characteristics of the analytical decision models used (perspective, time horizon, main health outcomes, analytical approach, discount rate application, sensitivity analysis), as well as (iv) main model conclusions and limitations.

The collected data were analyzed descriptively using Microsoft Excel 2010. For the nominal data, numbers and percentages are provided, while median and ranges are used for the ordinal data. No summary measures related to the incremental cost-effectiveness measures, which are not usually recommended in systematic reviews of economic analyzes, were calculated, given the methodological, population and interventions predictable differences between studies, which may generate significant heterogeneity of results²⁶.

The characteristics and results of the included studies were summarized using tables, complemented by a narrative summary that sought to compare and evaluate the methods used and the main results between the studies.

RESULTS

A total of 1,171 references were identified in the bibliographic databases searched. After eliminating 167 duplicate records, 1,004 abstracts were examined and 63 full-text articles were evaluated. Of these, 12 economic assessments met the eligibility criteria²⁷⁻³⁸ and were included in the review (Figure 1).

There was considerable variation in the countries where the evaluations were conducted, with five studies carried out in the United Kingdom. More than half of the studies were published from 2010 onwards. Data on the age of the simulated populations varied considerably, but 83.3% considered the study population to be 60 years or older (Table 1).


Cost-utility studies that measured outcomes in terms of cost per QALY gained were the predominant type of economic assessment (75%), and there were only two studies^{35,38}, both cost-effectiveness studies, in which results were expressed only in terms of cost per year of life with independence gained. Eleven studies included populations with moderate-severe

AD in their analysis. Six studies used more than one analytical perspective to assess costs and benefits; the perspective of society, in which all costs were computed, including those incurred by caregivers or due to loss of productivity of patients and their families, was adopted in seven studies (58.3%) while the health system perspective, in which only the costs incurred by the health care funder are considered, was used in seven (58.3%) studies, and social security costs were considered in three.

The main source of information on drug efficacy measures used to feed the models was previously published controlled clinical trials (75%).

As can be seen in Table 2, which summarizes the main characteristics of the models used in economic evaluations, a single study was conducted through a clinical trial (piggyback evaluation) and did not use modeling in its construction²⁷, while nine economic evaluations (75%) used Markov's approach as their analytical model.

The main measure of cost-effectiveness outcome was the quality-adjusted life year (QALY). Intermediate outcomes, such as cost per year or period of independence and cost per year without patient institutionalization, were used in three studies^{33,35,38} (Chart 2).



EE: Economic evaluations; AD: Alzheimer's Disease; ICER: Incremental cost-effectiveness ratio.

Figure 1. Flowchart of the search and selection process of studies included in the systematic review.

Chart 1. General characteristics of economic assessment studies included in the systematic review.

Author, year Country / Currency (year*)	Type of Economic Evaluation and Target Population	Perspective of Analysis	Intervention Examined Versus Comparator Used in Economic Evaluation /Effectiveness data source type	Costs included in economic assessment studies
Knapp et al., 2016 ²⁷ UK / € (2013/14)	ACU Moderate/ severe AD	Health System Society	MEMAN <i>vs</i> PL MEMAN + DON <i>vs</i> DON/RCCT	Direct: Drugs, Consultations, Hospitalization, Caregiver / Indirect ‡
Hyde et al., 2013 ²⁸ UK / £ (2009)	ACU Moderate/ severe AD	Health System	MEMAN <i>vs</i> absence of treatment*** (Systematic Review)	Direct: Drugs, appointments, hospitalization, other health professionals
Rive et al., 2012 ²⁹ Norway / € (2009)	ACU Moderate/ severe AD	Society Health System	MEMAN <i>vs</i> Ach** (Metanalysis)	Direct: Drugs, appointments, tests, hospitalization, caregiver, other health professionals / Indirect ‡
Hartz et al., 2012 ³⁰ Germany /€ (2011)	ACU Moderate AD	Society Social Security	MEMAN <i>vs</i> DON (RCCT)	Direct: Drugs, appointments, exams, hospitalization, caregiver, other health professionals, / Indirect: ‡
Bond et al., 2012 ³¹ UK /£ (2009)	ACU Moderate/ severe AD	Health System	MEMAN <i>vs</i> absence of treatment*** (Systematic review)	Direct: Drugs, consultations, hospitalization, caregiver, other health professionals, institutionalization costs, other support measures
Rive et al., 2010 ³² UK / £ (2008/2009)	ACU Moderate/ severe AD	Health System Social Security	MEMAN <i>vs</i> Ach** RCCT	Direct: Drugs, hospitalization, other health professionals
Gagnon et al., 2007 ³³ Canada / CAD\$ (2005)	ACU Moderate/ severe AD	Society	MEMAN <i>vs</i> absence of tto*** RCCT	Direct: Drugs, consultations, hospitalization, outpatient care, other health professionals, institutionalization costs, caregiver / Indirect ‡:
Weyker et al., 2007 ³⁴ USA / US\$ (2005)	ACU Moderate/ severe AD	Society	MEMAN + DON <i>vs</i> DON RCCT	Direct: Drugs, consultations, hospitalization, institutionalization costs, outpatient appointments / Indirect ‡
Antonanzas et al., 2006 ³⁵ Spain / € (2005)	ACE Moderate/ severe AD	Society	MEMAN <i>vs</i> absence of treatment*** RCCT	Direct: Medicines, Consultations, Hospitalization / Indirect ‡
Jonsson et al., 2005 ³⁶ Sweden / SEK (2004)	ACU Moderate/ severe AD	Health system	MEMAN <i>vs</i> PL RCCT	Direct: Drugs, consultations, hospitalization, health professionals.
François et al., 2004 ³⁷ Finland / € (2001)	ACE Moderate/ severe AD	Society	MEMAN <i>vs</i> PL RCCT	Direct: Drugs, consultations, hospitalization, caregiver, institutionalization costs, other health professionals / Indirect ‡
Jones et al., 2004 ³⁸ UK / £ (2003)	ACU Moderate/ severe AD	Health system Social security	MEMAN <i>vs</i> PL RCCT	Direct: Drugs, consultations, hospitalization, outpatient care, other health professionals, institutionalization costs

Ach: Cholinesterase inhibitor, ACE: cost-effectiveness, ACU: cost-utility, AD: Alzheimer's Disease; DON: donepezil, RCCT: Randomized Clinical Controlled Trial; USA: United States; MEMAN: memantine, PL: placebo; *Year in which costs were reported, **Author does not discriminate cholinesterase inhibitor; *** absence of specific pharmacological treatment; ‡ — Indirect costs involving costs of informal workers

Chart 2. General characteristics of the analytical decision model structures of the studies included in the systematic review.

Study / Year	Time horizon	Main Outcome / Measures	Analytical Approach: Model, States/Cycle Length	Discount rate (%) Costs / Benefits
Hyde et al., 2013 ²⁸	20 years	Cost/QALY	Markov 3 states (pre-institutionalized, institutionalized and dead)/ 12 months	No Information
Rive et al., 2012 ²⁹	5 years	Cost/QALY	Markov 3 states (pre-institutionalized, institutionalized and dead)/ 1 month	3 / 3
Hartz et al., 2012 ³⁰	10 years	Cost/QALY	Discrete-event simulation	3 / 3
Bond et al., 2012 ³¹	20 years	Cost/QALY	Markov 3 states (pre-institutionalized, institutionalized and dead)/ 12 months	3.5 / 1.5
Rive et al., 2010 ³²	5 years	Cost/QALY	Markov 3 states (pre-institutionalized, institutionalized and dead)/ 1 month	3.5 / 3.5
Gagnon et al., 2007 ³³	2 years	Cost/QALY Cost/year of independence	Markov 5 states (combination of severity and independence and dead stages) / 6 months	5 / 5
Weyker et al., 2007 ³⁴	6 months / 1 year / 1.5 years / 2 years / Lifetime	Cost/QALY	Discrete-event simulation	3 / 3
Antonanzas et al., 2006 ³⁵	2 years	Cost/year of independence	Markov 6 states (combination of severity and independence and dead stage) / 6 months	6 / 6
Jonsson, 2005 ³⁶	5 years	Cost/QALY	Markov 13 states (combination of three variables: severity, independence, institutionalization status, and dead) / 6 months	3 / 3
François et al., 2004 ³⁷	5 years	Cost/year of independence gained Cost/year without institutionalization	Markov 13 states (combination of severity, independence, institutionalization status, and dead) / 6 months	5 / 5
Jones et al., 2004 ³⁸	2 years	Cost/QALY	Markov 13 states (combination of three variables: severity, independence, institutionalization status, and dead) / 6 months	3.5 / 3.5

QALY: Quality-adjusted life-year;

Eight studies (66.6%) employed in its analysis a time horizon of five years or more, two had a time horizon of 20 years^{28,31} and one used lifetime³⁴.

The number of Markov states and the duration of cycles varied between publications. Four studies (33.3%) considered only three health states (pre-institutionalized, institutionalized and dead)^{28,29,31,32}.

The main study designs used to investigate the progression of AD and the likelihood of change in health status were clinical trials and observational studies from population-based registries.

The scales used for the clinical evaluation of AD and the domains considered differed greatly between studies. The cognitive approach and measures related to activities of daily living, in addition to behavior, were the main competences included.

Regarding the main findings of the economic assessments included, the results of the use of memantine was considered cost-effective and

dominant, i.e., less costly and more effective than its comparator, in nine studies (75%), as shown in Chart 3. In one study only²⁸, memantine was not cost-effective when compared to donepezil in the moderate AD population, defined by the MMSE scores of ≥ 10 and < 25 (Table 3).


A sensitivity analysis to examine the uncertainty regarding the parameters and structure of the models was included in all studies, with deterministic analyses being the most used (66.6%); while extreme scenario analyses were included in two studies^{33,36}.

The methodological quality of the included studies was considered good (Figure 2). The worst quality items were the justifications for choosing the discount rate adopted, details of the statistical methods and the disaggregated presentation of results. All the manuscripts presented arguments regarding the limitations of their study. In addition, 80% declared a conflict of interest and funding in their publications. Most manuscripts were funded by industry (75%).

Chart 3. Main results of economic assessments and uncertainty analyzes

Author	Main results	Sensitivity Analysis
Knapp et al., 2016 ²⁷	ICER*/ HS: MEMAN <i>vs</i> dominant PL / MEMAN +DON <i>vs</i> DON cost-effective; Soc. MEMAN+DON <i>vs</i> DON non-cost-effective	Acceptability C.: Chance 95% MEMAN cost-effective <i>vs</i> PL with threshold of £30,000 and of 55% of MEMAN + DON <i>vs</i> DON cost-effective with same threshold
Hyde et al., 2013 ²⁸	ICER £32,100/QALY / MEMAN cost-effective <i>vs</i> no specified treatment	Acceptability C.: Chance of 38% MEMAN cost-effective <i>vs</i> no treatment with threshold of €30,000
Rive et al., 2012 ²⁹	Negative ICER ** / MEMAN dominant <i>vs</i> Ach***	Deterministic: MEMAN dominant <i>vs</i> Ach*** Probabilistic: Chance >98% of MEMAN being cost-effective
Hartz et al., 2012 ³⁰	MEMAN non-cost-effective and dominated by DON Δ costs DON: -€2,225 / Δ QALY: 0.017	Deterministic: DON dominant <i>vs</i> MEMAN in all simulations Probabilistic: Chance >70% of DON dominating MEMAN Acceptability C.: Chance >90% of DON cost-effective with threshold of €10,000
Bond et al., 2012 ³¹	ICER*£32,100/QALY / MEMAN cost-effective <i>vs</i> no specified treatment	Deterministic: MEMAN cost-effective; MEMAN effectiveness alters ICER Acceptability C.: Chance 38% MEMAN cost-effective with threshold of £30,000
Rive et al., 2010 ³²	ICER negative** / MEMAN cost-effective <i>vs</i> Ach*** Δ costs: -£1,711/ Δ QALY: 0.031	Deterministic: MEMAN dominant <i>vs</i> Ach*** Probabilistic: Chance >99% MEMAN being cost-effective Acceptability C.: Chance >98% MEMAN cost-effective with threshold of €20,000
Gagnon et al., 2007 ³³	ICER negative** / MEMAN cost-effective <i>vs</i> no treatment Δ costs: -CAD\$1,276 / Δ QALY: 0.031 / Δ years without complete dependence: 0.09	Deterministic: MEMAN dominant <i>vs</i> no treatment Probabilistic: MEMAN cost-neutral in 83.3% Acceptability C.: Chance 89.5% MEMAN cost-effective with threshold of €20,000
Weyker et al., 2007 ³⁴	ICER*: TH of 6m: 3.475 / TH of 12m: 382 / TH de 18m: -5.102 / TH entire life: -US\$8,880 / MEMAN + DON is cost-effective <i>vs</i> DON	Deterministic: MEMAN cost-effective and dominant <i>vs</i> DON
Antonanzas et al., 2006 ³⁵	ICER negative** / MEMAN cost-effective <i>vs</i> no treatment Δ costs: -€667 / Δ years independence gained: 0.202	Acceptability C.: Chance >98% MEMAN cost-effective <i>vs</i> PL with threshold of €30,000
Jonsson, 2005 ³⁶	ICER negative** / MEMAN cost-effective <i>vs</i> PL Δ costs: -SEK100,528 / Δ QALY: 0,148	Deterministic: MEMAN dominant <i>vs</i> PL Extreme scenario analysis: MEMAN dominant
François et al., 2004 ³⁷	ICER negative** / MEMAN cost-effective <i>vs</i> PL Δ costs: -€1,687 / Δ years of independence: 0.34	Probabilistic: Chance >93% MEMAN <i>vs</i> PL cost-effective and dominant Acceptability C.: Chance >99% MEMAN cost-effective with threshold of €30,000
Jones et al., 2004 ³⁸	ICER negative** / MEMAN cost-effective <i>vs</i> PL Δ costs: -£1,963 / Δ QALY: 0.04	Deterministic univariate: MEMAN cost-effective <i>vs</i> PL in all scenarios

Acceptability C.: Acceptability Curve; DON: Donepezil; MEMAN: Memantine; PL: Placebo; TH: Time Horizon; QALY: Quality-adjusted life-year; ICER: Incremental cost-effectiveness ratio; HS: Healthcare System; Soc: Society; Δ: Difference; *vs*: versus; *ICER: Incremental cost-effectiveness ratio; Negative ICER **: use of intervention represents resource savings compared with comparator; Ach***: Non-specified inhibitors



EE: Economic Evaluations; CI: Confidence Intervals

Figure 2. Assessment of methodological quality of economic evaluation studies included.

DISCUSSION

The increase in health-related costs in a scenario of limited resources, as well as the growing prevalence of Alzheimer's disease associated with population aging, mean it is imperative to examine the relationship between costs and clinical benefits the drugs used in their treatment, especially when evidence of the efficacy of therapy isn't strong and the benefits are considered insufficient.

A systematic review of the risk-benefit of inhibitors and memantine use in AD states that its benefits are marginal and short-termed, indicating that it should be used cautiously in the elderly population, where side effects may be more significant, especially with inhibitors of the drugs¹⁷. Some health systems do not include or have withdrawn memantine funding for the treatment of moderate to severe stages of disease^{18,19}. Others restrict this funding to fixed time periods (eg, one year), during which users

are periodically reassessed, with the suspension of coverage if there is evidence of disease progression supported by the application of certain scales such as the Mini-Mental State Exam (MMSE) and the Clinical Dementia Rating (CDR)³⁹.

Considering the incremental cost-effectiveness ratios and cost-effectiveness thresholds defined in each country, the results showed that the use of memantine for moderate to severe AD was considered cost-effective in most studies, being the dominant therapeutic strategy in eleven articles, that is, less costly and with better health outcomes. Sensitivity analyzes concerning the variation of a large number of parameters reinforce the fact that these results were robust, that is, they remained favorable to memantine.

It should be noted, however, that all studies were conducted in developed countries and mostly applied the societal perspective, computing costs that included caregiver time, costs incurred by families and productivity losses associated disease, whether by patients or family members.

The incremental cost-effectiveness ratios resulting from the analyzes varied widely. This variability possibly resulted from aspects related to study design, the perspective adopted and the assumptions considered, resulting in limitations related to the comparability between studies.

The results are consistent with some reviews already available on the subject. In 2018, a systematic review published by Ebrahim and Oremus¹⁶ on economic assessments related to the treatment of AD identified 14 studies related to the use of memantine alone or combined with anticholinesterases, with 93.7% of the studies also finding that memantine was cost-effective.

A single study included in the present review concluded that the strategy of using memantine alone was dominated by donepezil for moderate AD, or in other words, the inhibitors had comparatively lower costs and better health outcomes³⁰. Sensitivity analyzes reinforced the robustness of these results, being favorable to donepezil based on variations in the parameters, with the acceptability curve showing a greater than 90% chance of inhibitor

being cost-effective at a threshold as low as €10,000.00 (2011 figures).

The study by Hartz et al.³⁰, conducted in Germany with a ten-year time horizon, used discrete-event simulation to capture, from the societal perspective, the costs and effects of treatment with respect to activities of daily living, improvements in function measured by MMSE and in the neuropsychiatric inventory. Unlike the other evaluations, the target population considered had moderate AD, the clinical stage of the disease in which the effects of memantine in isolation remain controversial⁴⁰.

The included studies that examined memantine in combination with donepezil also indicated divergent cost-effectiveness results between studies, depending on the reference population^{27,34}. The study by Knapp et al.²⁷, an economic evaluation performed in parallel with a controlled clinical trial published in 2016, showed that the memantine-donepezil combination was not cost-effective compared to donepezil alone for moderate disease²³. The study by Weyker et al.³⁴, meanwhile, conducted in the US using discrete-event simulation, showed that this association was cost-effective for moderate and severe AD, considering time horizons greater than six months. In addition to examining diverse patient populations, the study designs were also distinct, which may have contributed to the difference in outcomes observed.

Markov's approach was the main type of modeling employed in the economic assessments examined (75%). The use of Markov chains is frequently recommended for modelling chronic diseases, where individuals move between different stages of the disease over time, reflecting their natural history⁴¹.

The simulated time horizons in the studies ranged from two years to lifetime, with most having horizons of five years or more. Considering that AD has a median survival period of 8.3 years in patients diagnosed aged 65 and over⁴², the chosen horizons mostly contemplate the life expectancy of these patients and can adequately capture the most relevant costs and benefits expected from the treatments used.

The cognitive domain is a relevant outcome in the natural course of the Alzheimer's disease progression

process and should be adopted in the modeling of this disease. However, modeling should also adopt domains other than the cognitive in order to consider the complexity of this disorder.

Literature suggests that modeling including aspects related to function, level of patient's dependence on a caregiver and quality of life may more accurately reflect the progression of AD⁴³. Clinical trials, commonly used as a data source in the economic evaluations found, are often insufficient and too short to evaluate such results, for which economic health models that combine trial data with real-world evidence are particularly useful⁴⁴.

The vast majority of the evaluations present in this review used, as an outcome of the cost-effectiveness of the intervention, quality-adjusted life years, whether alone or combined with other dimensions. QALY is a multidimensional concept whose use is particularly important in chronic conditions, and especially when the results of the intervention affect survival less and the domains of relationships and living more (cognition, mood, behavior, functionality and the ability to live longer without requiring special care or institutionalization), as observed in AD⁴⁵. However, some studies suggest that QALY may not be fully accurate for the evaluation of individuals living with AD, as it is often caregivers, and non-patients, who provide proxy measures⁴⁶.

There is a relative scarcity of data related to the use of drugs such as memantine and donepezil and their effects on delaying institutionalization⁴⁷. In addition, the reasons leading to the institutionalization of AD patients are multifactorial and complex, involving patient and caregiver characteristics, and the social and cultural environment. These types of outcomes are not usually evaluated in clinical trials, have significant impacts on health costs, and may underestimate overall cost measures, particularly the indirect costs of AD patient care⁴⁸.

Finally, it should be mentioned that most evaluations assumed that the drugs did not have an effect on mortality, which was supported by the fact that symptomatic therapies generally had no effect on the underlying disease process, and the lack of

evidence of such an effect from relatively short-term clinical trials.

Most of the evaluations used randomized controlled trials as a source of data on the effectiveness of treatment. This can set a good internal validity in the model construction, but has a low external validity, since most trials have a short duration and cannot add long-term treatment effects. In addition, the use of parameters from a clinical trial conducted in one country in evaluations performed in another may pose a problem in generalizing modeling results, which is further accentuated when measures are applied as utilities to generate QALY.

Few economic models used in the simulations contemplated the scope of the natural history of AD. There is great variability in the assumptions made in these studies, in their effectiveness and cost data sources, their utility measure calculations and the transparency of their models. Therefore, caution is advised regarding the conclusions of the present review.

Finally, the number of economic evaluations funded by the pharmaceutical industry in which their drugs dominated their comparators was high, increasing the risk of possible publication bias.

CONCLUSIONS

Most of the economic assessments included in this review indicate that the use of memantine alone or combined with donepezil for moderate to severe Alzheimer's disease is predominantly cost-effective in countries where the studies were conducted. Although most uncertainty analyzes confirm the robustness of the results presented, caution is required when transferring cost-effectiveness findings from one country to another, either because of the difficulty of extrapolating data costs due to different payment structures and systems and national incentives, or because considering a cost-effective strategy is closely related to the cost-effectiveness thresholds implicitly or explicitly adopted in each country. The fact that most evaluations are funded by industry highlights that studies may contain significant biases and,

for that reason, caution should be exercised in the process of interpreting these results.

Therefore, local-based analyzes should be performed in Brazil, paying close attention to the

issues and limitations raised from the economic evaluations already performed, so that the cost-effectiveness of memantine, whether combined or not with donepezil, for severe Alzheimer's Disease is more accurately assessed.

Edited by: Ana Carolina Lima Cavaletti

13 of 15

REFERENCES

- dos Santos Picanço LC, Ozela PF, de Brito Brito MF, Pinheiro AA, Padilha EC, Braga FS, et al. Alzheimer's disease: a review from the pathophysiology to diagnosis, new perspectives for pharmacological treatment. *Curr Med Chem*. 2018;28:3141-59.
- Gutierrez BAO, Silva HS, Guimarães C, Campino AC. Impacto econômico da doença de Alzheimer no Brasil: é possível melhorar a assistência e reduzir os custos? *Ciênc Saúde Colet*. 2014;19(11):4479-86.
- Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, et al. Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria. *J Intern Med*. 2014;275(3):304-16.
- Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement*. 2013;9(1):63-75.
- Alves JED. Transição demográfica, transição da estrutura etária e envelhecimento. *Rev Portal Divulg*. 2014;40:1-8. Disponível em: www.portaldoenvelhecimento.org.br/revista
- Burla C, Camarano AA, Kanso S, Fernandes D, Nunes R. Panorama prospectivo das demências no Brasil: um enfoque demográfico. *Ciênc Saúde Colet*. 2013;18(10):2949-56.
- Brasil. Portaria conjunta nº 13 de 28 de novembro de 2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Alzheimer. *Diário Oficial da União*. 08 de dezembro de 2017. Seção 1. Pág. 201.
- Puangthong U, HsiungGing-YueK R. Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. *Neuropsychiatr Dis Treat*. 2009;5:553-61.
- Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). *Int J Geriatr Psychiatry*. 1999;14(2):135-46.
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine to moderate to severe Alzheimer's disease. *N Engl J Med*. 2013;348(14):1333-41.
- Van Dyck CH, Tariot PN, Meyers B, Malca Resnick E; Memantine MEM-MD-01 Stud Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. *Alzheimer Dis Assoc Disord*. 2007;21(2):136-43.
- Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer's Disease: an updated systematic review and meta-analysis. *J Alzheimers Dis*. 2017;60(2):401-25.
- Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis. *PLoS One*. 2017;12(8):e 0183586 [14p.].
- Tsoi KK, Chan JY, Leung NW, Hirai HW, Wong SY, Kwok TC. Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: a Meta-analysis of 14 Randomized Trials. *J Am Med Dir Assoc*. 2016;17(9):1-8.
- Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. *Neuropsychiatr Dis Treat*. 2017;13:1909-28.
- Ebrahim AS, Oremus M. A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease. *Expert Opin Pharmacother*. 2018;19(11):1245-59.
- Buckley JS, Salpeter SR. A Risk-Benefit assessment of dementia medications: systematic review of the evidence. *Drugs Aging*. 2015;32(6):453-67.
- Prescrire Rédaction. Médicaments de la maladie d'Alzheimer: enfin non remboursables en France. *Rev Prescrire [Internet]*. 2018 [acesso em 08 ago. 2019];38(416):1-2. Disponível em: <https://www.prescrire.org/fr/3/31/55116/0/NewsDetails.aspx>
- France. Haute Autorité de Santé. Guide parcours de soins des patients présentant un trouble neurocognitif associé à la maladie d'Alzheimer ou à une maladie apparentée [Internet]. Saint Denis: HAS; 2018 [acesso em 08 ago. 2019]. Disponível em: https://www.has-sante.fr/upload/docs/application/pdf/2018-05/parcours_de_soins_alzheimer.pdf

20. National Institute for Health Care and Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Technology appraisal guidance [TA217] [Internet]. London: NICE; 2018. [acesso em 08 ago. 2019]. Disponível em <https://www.nice.org.uk/guidance/TA217>
21. Brasil. Ministério da Saúde. Portaria GM/MS nº 843, de 31 de outubro de 2002. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Alzheimer. Diário Oficial da União. 04 nov. 2002.
22. Costa RDF, Osório-de-Castro CGS, Silva RM, Maia AA, Ramos MCB, Caetano R. Aquisição de medicamentos para a Doença de Alzheimer no Brasil: uma análise no sistema federal de compras, 2008 a 2013. *Ciênc Saúde Colet*. 2015;20(12):3827-38.
23. Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos, Departamento de Gestão e Incorporação de Tecnologias em Saúde. Entendendo a incorporação de tecnologias em Saúde no SUS: como se envolver [Internet]. Brasília, DF: Ministério da Saúde; 2016.
24. Galvão TF, Panzani TSA. Principais itens para relatar Revisões sistemáticas e Meta-análises: a recomendação PRISMA*. *Epidemiol Serv Saúde*. 2015;24(2):335-42.
25. Drummond M. Guidelines for authors and peer reviewers of economic submissions to the BMJ. *BMJ*. 1996;313:275-83.
26. Luhn M, Prediger B, Neugebauer EAM, Mathes T. Systematic reviews of economic evaluations in health technology assessment: a review of characteristics and applied methods. *Int J Technol Assess Health Care*. 2018;34(6):537-46.
27. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). *Int J Geriatr Psychiatry*. 2016;32(12):1205-16.
28. Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model. *Age Ageing*. 2013;42(1):14-20.
29. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. *Int J Geriatr Psychiatry*. 2012;27(6):573-82.
30. Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation. *BMC Neurol*. 2012;1-12.
31. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. *Health Technol Assess*. 2012;16(21):1-47.
32. Rive B, Grishchenko M, Guillaume-Goulant C, Katona C, Livingston G, Lamure M, et al. Cost effectiveness of memantine in Alzheimer's disease in the UK. *J Med Econ*. 2010;13(2):371-80.
33. Gagnon M, Rive B, Hux M, Guillaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer Disease in Canada. *Can J Psychiatry*. 2007;52(8):519-26.
34. Weyker D, Taneja C, Edelsberg J, Haim Erder M, Schmitt FA, Setyawan J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. *Curr Med Res Opin*. 2007;23(5):1187-97.
35. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guillaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain. *Eur J Health Econ*. 2006;7(2):137-44.
36. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. *Am J Geriatr Pharmacother*. 2005;3(2):77-86.
37. François C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's Disease: a Markov Model in Finland. *Clin Drug Investig*. 2004;24(7):373-84.
38. Jones RW, McCrone P, Guillaume C. Cost Effectiveness of Memantine in Alzheimer's Disease: an analysis based on a probabilistic Markov Model from a UK Perspective. *Drugs Aging*. 2004;21(9):607-20.
39. Green C, Zhang S. Predicting the progression of Alzheimer's disease dementia: a multidomain health policy model. *Alzheimers Dement*. 2016;12(7):776-85.
40. Jiang J, Jiang H. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials. *Neurol Sci*. 2015;36(9):1633-41.

41. Soárez PC, Soares MO, Novaes HMD. Modelos de decisão para avaliações econômicas de tecnologias em saúde. *Ciênc Saúde Colet*. 2014;19(10):4209-22.
42. Teixeira JB, de Souza Júnior PRB, Higa J, Theme Filha MM. Doença de Alzheimer: estudo da mortalidade no Brasil, 2000-2009. *Cad Saúde Pública*. 2015;31(4):1-12.
43. Green C, Zhang S. Predicting the progression of Alzheimer's disease dementia: a multidomain health policy model. *Alzheimers Dement*. 2016;12(7):776-85.
44. Wimo A. Long-term effects of Alzheimer's disease treatment. *Lancet Neurol*. 2015;14(12):1145-6.
45. Ratcliffe J, Hutchinson C, Milte R, Nguyen KH, Welch A, Caporale T, et al. How do people with dementia and family carers value dementia-specific quality of life states?: An explorative "Think Aloud" study. *Australas J Ageing*. 2019;38(Suppl 2):75-82.
46. Nickel F, Barth J, Kolominsky-Rabas PL. Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review. *BMC Geriatrics*. 2018;18(69):2-18.
47. Howard R, McShane R, Lindsay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. *Lancet Neurol*. 2015;14(12):1171-81.
48. Jones RW, Romeo R, Trigg R, Knapp M, Sato A, King D, et al. Dependence in Alzheimer's disease and service use costs, quality of life, and caregiver burden: the DADE study. *Alzheimers Dement*. 2015;11(3):280-90.